Name
Globalex Pharma OÜ
Registry code
11505401
VAT number
EE101258939
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
16.05.2008 (16)
Financial year
01.01-31.12
Capital
2 556.00 €
Activity
46461 - Wholesale of medicines and other pharmacy goods 82991 - Other business support service activities n.e.c.
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| GLOBALEX HOLDING OÜ 11504005 | 100% - 2 556.00 EUR | - | - | Founder |
| Ivari Saar 04.05.1985 (39) | - | Board member | Indirect ownership | |
| Jevgeni Stasjuk 04.01.1987 (37) | - | - | Indirect ownership | |
| Polina Stasjuk 07.01.1989 (35) | - | - | Indirect ownership |
| 2019 30.06.2020 | 2020 30.06.2021 | 2021 28.12.2023 | 2022 13.01.2024 | |
|---|---|---|---|---|
| Total Revenue | 1 099 674 € | 1 610 898 € | 1 832 803 € | 7 899 136 € |
| Net profit (loss) for the period | 65 798 € | 88 582 € | -87 206 € | 252 806 € |
| Profit Margin | 6% | 5% | -5% | 3% |
| Current Assets | 317 133 € | 494 378 € | 693 790 € | 906 617 € |
| Fixed Assets | - | - | 61 449 € | 26 446 € |
| Total Assets | 317 133 € | 494 378 € | 755 239 € | 933 063 € |
| Current Liabilities | 88 503 € | 177 166 € | 438 944 € | 423 395 € |
| Non Current Liabilities | - | - | 86 289 € | 26 857 € |
| Total Liabilities | - | - | 525 233 € | 450 252 € |
| Share Capital | - | - | - | - |
| Equity | 228 630 € | 317 212 € | 230 006 € | 482 811 € |
| Employees | 1 | 1 | 2 | 2 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 474 564.41 € | 32 012.89 € | 7 989.29 € | 5 |
| 2023 Q4 | 300 359.76 € | 50 114.06 € | 8 686.92 € | 5 |
| 2023 Q3 | 568 523.28 € | 52 930.93 € | 7 356.96 € | 5 |
| 2023 Q2 | 521 129.97 € | 37 765.13 € | 6 066.75 € | 4 |
| 2023 Q1 | 599 914.75 € | 44 993.49 € | 6 206.67 € | 4 |
| 2022 Q4 | 237 095.32 € | - | 6 241.66 € | 4 |
| 2022 Q3 | 1 207 374.7 € | 210 591.49 € | 4 457.45 € | 3 |
| 2022 Q2 | 1 057 208.87 € | - | 3 103.54 € | 3 |
| 2022 Q1 | 1 661 093.25 € | 978.1 € | 2 871.62 € | 3 |
| 2021 Q4 | 193 427.05 € | - | 1 990.34 € | 3 |
| 2021 Q3 | 888 044.58 € | - | 2 466.71 € | 3 |
| 2021 Q2 | 468 967.23 € | - | 1 333.11 € | 3 |
| 2021 Q1 | 660 103.23 € | - | 888.74 € | 3 |
| 2020 Q4 | 360 151.84 € | - | 888.74 € | 3 |
| 2020 Q3 | 907 650.72 € | - | 888.74 € | 3 |
| 2020 Q2 | 411 716.64 € | 8 896.94 € | 5 180.2 € | 1 |
| 2020 Q1 | 108 018.57 € | 2 893.71 € | 3 034.48 € | 1 |
